Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: A retrospective clinical study and review of the literature

Endocrine Journal

Volumn 60, Issue 4, 2013, Pages 507-515

  Suda, Kentaro ^a   Inoshita, Naoko ^b   Iguchi, Genzo ^a   Fukuoka, Hidenori ^a   Takahashi, Michiko ^a   Nishizawa, Hitoshi ^a   Yamamoto, Masaaki ^a   Yamada, Shozo ^b   Takahashi, Yutaka ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TORANOMON HOSPITAL   (Japan)

Author keywords

Acromegaly; Cabergoline; Combined therapy; Octreotide; Prolactin (PRL)

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE 2 RECEPTOR; GROWTH HORMONE; OCTREOTIDE; PROLACTIN; SOMATOMEDIN C; SOMATOSTATIN RECEPTOR;

ACROMEGALY; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; ENDOCRINE FUNCTION TEST; FEMALE; GALLBLADDER DISEASE; GROWTH HORMONE BLOOD LEVEL; HORMONE RESPONSE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NAUSEA; OUTCOME ASSESSMENT; PATIENT SELECTION; PROLACTIN BLOOD LEVEL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; TREATMENT DURATION; TUMOR VOLUME;

ACROMEGALY; ADENOMA; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DELAYED-ACTION PREPARATIONS; DRUG RESISTANCE; ERGOLINES; FEMALE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; INSULIN-LIKE GROWTH FACTOR I; JAPAN; MALE; MIDDLE AGED; OCTREOTIDE; PITUITARY GLAND; RETROSPECTIVE STUDIES; SOMATOSTATIN; TUMOR BURDEN; YOUNG ADULT;

EID: 84877006408     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Colao A, Lombardi G (1998) Growth-hormone and prolactin excess. Lancet 352: 1455-1461.
2. Holdaway IM, Bolland MJ, Gamble GD (2008) A metaanalysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 159: 89-95.
3. Chanson P, Salenave S, Kamenicky P, Cazabat L, Young J (2009) Pituitary tumours: acromegaly. Best Pract Res Clin Endocrinol Metab 23: 555-574.
4. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, et al. (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94: 1509-1517.
5. Ben-Shlomo A, Melmed S (2008) Somatostatin agonists for treatment of acromegaly. Mol Cell Endocrinol 286: 192-198.
6. Colao A, Auriemma RS, Lombardi G, Pivonello R (2011) Resistance to somatostatin analogs in acromegaly. Endocr Rev 32: 247-271.
7. Bevan JS, Webster J, Burke CW, Scanlon MF (1992) Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 13: 220-240.
8. Moyes VJ, Metcalfe KA, Drake WM (2008) Clinical use of cabergoline as primary and adjunctive treatment for acromegaly. Eur J Endocrinol 159: 541-545.
9. Freda PU (2003) How effective are current therapies for acromegaly? Growth Horm IGF Res 13 Suppl A: S144-151.
10. Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, et al. (1998) Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 83: 374-378.
11. Vilar L, Czepielewsk MA, Naves LA, Rollin GA, Casulari LA, et al. (2007) Substantial shrinkage of adenomas cosecreting growth hormone and prolactin with use of cabergoline therapy. Endocr Pract 13: 396-402.
12. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, et al. (2001) Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358: 1754-1759.
13. van der Lely AJ, Biller BM, Brue T, Buchfelder M, Ghigo E, et al. (2012) Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab 97: 1589-1597.
14. Marzullo P, Ferone D, Di Somma C, Pivonello R, Filippella M, et al. (1999) Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. Pituitary 1: 115-120.
15. Cozzi R, Attanasio R, Lodrini S, Lasio G (2004) Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf) 61: 209-215.
16. Gatta B, Hau DH, Catargi B, Roger P, Tabarin A (2005) Re-evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patients. Clin Endocrinol (Oxf) 63: 477-478.
17. Jallad RS, Bronstein MD (2009) Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide. Neuroendocrinology 90: 82-92.
18. Mattar P, Alves Martins MR, Abucham J (2010) Shortand long-term efficacy of combined cabergoline and octreotide treatment in controlling igf-I levels in acromegaly. Neuroendocrinology 92: 120-127.
19. Vilar L, Azevedo MF, Naves LA, Casulari LA, Albuquerque JL, et al. (2011) Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR. Pituitary 14: 148-156.
20. Isojima T, Shimatsu A, Yokoya S, Chihara K, Tanaka T, et al. (2012) Standardized centile curves and reference intervals of serum insulin-like growth factor-I (IGF-I) levels in a normal Japanese population using the LMS method. Endocr J 59: 771-780.
21. Lundin P, Pedersen F (1992) Volume of pituitary macroadenomas: assessment by MRI. J Comput Assist Tomogr 16: 519-528.
22. Volante M, Brizzi MP, Faggiano A, La Rosa S, Rapa I, et al. (2007) Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 20: 1172-1182.
23. Takei M, Suzuki M, Kajiya H, Ishii Y, Tahara S, et al. (2007) Immunohistochemical detection of somatosta tin receptor (SSTR) subtypes 2A and 5 in pituitary adenoma from acromegalic patients: good correlation with preoperative response to octreotide. Endocr Pathol 18: 208-216.
24. Kato M, Inoshita N, Sugiyama T, Tani Y, Shichiri M, et al. (2012) Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas. Endocr J 59: 221-228.
25. Sandret L, Maison P, Chanson P (2011) Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab 96: 1327-1335.
26. Colao A, Ferone D, Marzullo P, Di Sarno A, Cerbone G, et al. (1997) Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab 82: 518-523.
27. Ferrari C, Paracchi A, Romano C, Gerevini G, Boghen M, et al. (1988) Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients. Clin Endocrinol (Oxf) 29: 467-476.
28. Flogstad AK, Halse J, Bakke S, Lancranjan I, Marbach P, et al. (1997) Sandostatin LAR in acromegalic patients: long-term treatment. J Clin Endocrinol Metab 82: 23-28.
29. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, et al. (2001) Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 86: 2779-2786.
30. Casarini AP, Jallad RS, Pinto EM, Soares IC, Nonogaki S, et al. (2009) Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment. Pituitary 12: 297-303.
31. Colao A, Pivonello R, Auriemma RS, Galdiero M, Savastano S, et al. (2007) Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol 157: 579-587.